• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Scholar Rock Holding Corporation (Amendment)

    2/9/24 4:47:28 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    SC 13G/A 1 d757129dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO 13d-2 (b)

    (Amendment No. 3)

     

     

    Scholar Rock Holding Corporation

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    80706P103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP #80706P103    Page 2 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Partners VI, L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    2,406,309 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    2,406,309 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,406,309 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.3% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    2,123,347 of such shares are held of record by PVP VI (as defined in Item 2(a) of the Original Schedule 13G) and 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment (as defined below). PVM VI (as defined in Item 2(a) of the Original Schedule 13G), the general partner of PVP VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 72,426,220 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2023, filed with the US Securities and Exchange Commission (the “Commission”) on November 7, 2023 (the “Form 10-Q”) plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 3 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Partners Founders’ Fund VI, L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    140,616 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    140,616 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    140,616 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.2% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    124,080 of such shares are held of record by PVPFF VI (as defined in Item 2(a) of the Original Schedule 13G) and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 72,159,794 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 4 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Venture Management Co VI, L.L.C.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    2,546,925 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    2,546,925 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,546,925 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.5% (2)

    12   

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 72,442,756 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iii) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 5 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    David Barrett

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    2,546,925 (1)

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    2,546,925 (1)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,546,925 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.5% (2)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 72,442,756 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iii) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 6 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Brian Chee

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    39,339 (1)

        6   

    SHARED VOTING POWER

     

    2,546,925 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    39,339 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    2,546,925 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,586,264 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.6% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Brian Chee directly.

    (2)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 72,442,756 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iii) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 7 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Jonathan A. Flint

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    2,546,925 (1)

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    2,546,925 (1)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,546,925 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.5% (2)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 72,442,756 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iii) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 8 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Terrance G. McGuire

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    39,123 (1)

        6   

    SHARED VOTING POWER

     

    2,546,925 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    39,123 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    2,546,925 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,586,048 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.6% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    12,858 of such shares are held by Terrance G. McGuire directly and 26,265 of such shares are held by the McGuire Family 2008 GST Non-Exempt Irrevocable Trust.

    (2)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 72,442,756 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iii) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 9 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Amir Nashat

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    104,780 (1)

        6   

    SHARED VOTING POWER

     

    2,546,925 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    104,780 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    2,546,925 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,651,705 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.7% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    Consists of (i) 25,506 shares held of record directly by Amir Nashat and (ii) 79,274 shares subject to stock option awards that have been granted to Amir Nashat in his capacity as a director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment. Excludes 36,000 shares subject to stock option awards that have been granted to Amir Nashat in his capacity as a director of the Issuer and that are not exercisable as of or within 60 days of the filing of this Amendment.

    (2)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 72,522,030 shares of the Issuer’s Common Stock, calculated as follows: (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 79,274 shares of the Issuer’s Common Stock subject to stock option awards that have been granted to Amir Nashat in his capacity as a director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment plus (iii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iv) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    Page 10 of 14

     

     1   

    NAME OF REPORTING PERSONS

     

    Bryce Youngren

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    27,299 (1)

        6   

    SHARED VOTING POWER

     

    2,546,925 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    27,299 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    2,546,925 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,574,224 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.6% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Bryce Youngren directly.

    (2)

    2,123,347 of such shares are held of record by PVP VI, 282,962 of such shares are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment, 124,080 of such shares are held of record by PVPFF VI and 16,536 of such shares are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment. PVM VI, the general partner of each of PVP VI and PVPFF VI, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Jonathan A. Flint, Terrance G. McGuire, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PVM VI and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 72,442,756 shares of the Issuer’s Common Stock, calculated as follows (i) 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 282,962 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVP VI and which is exercisable within 60 days of the filing of this Amendment plus (iii) 16,536 shares of the Issuer’s Common Stock are shares underlying a warrant issued to PVPFF VI and which is exercisable within 60 days of the filing of this Amendment.


    CUSIP #80706P103    SCHEDULE 13G    Page 11 of 14

     

    Introductory Note: This Amendment No. 3 (the “Amendment”) amends and supplements the Schedule 13G originally filed by the Reporting Persons with the Commission on February 14, 2019, Amendment No. 1 filed with the Commission on February 11, 2022 and Amendment No. 2 filed with the Commission on February 7, 2023 (collectively, the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G.

    ITEM 1(B). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    301 Binney Street, 3rd Floor

    Cambridge, MA 02142

    ITEM 2(B). ADDRESS OF PRINCIPAL OFFICE

    The address for each of the Reporting Persons except for Chee is:

    c/o Polaris Partners

    One Marina Park Drive, 8th Floor

    Boston, MA 02210

    The address for Chee is:

    c/o Polaris Partners

    1 Letterman Drive

    Building C, Suite 3600

    San Francisco, CA 94129

    ITEM 4. OWNERSHIP 

    The approximate percentages of Common Stock reported as beneficially owned by the Reporting Persons are based upon 72,143,258 shares of the Issuer’s Common Stock outstanding as of November 2, 2023, as reported on the Form 10-Q.

    The following information with respect to the ownership of the common stock of the Issuer by the Reporting Persons filing this Statement is provided as of December 31, 2023:

    (a) Amount beneficially owned:

     

    See

    Row 9 of cover page for each Reporting Person.

    (b) Percent of Class:

     

    See

    Row 11 of cover page for each Reporting Person.

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.


    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    *

    Except to the extent of their pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    ☒


    CUSIP #80706P103    Page 13 of 14

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 9, 2024

     

    POLARIS VENTURE PARTNERS VI, L.P.
    By:   Polaris Venture Management Co. VI, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS VENTURE PARTNERS FOUNDERS’ FUND VI, L.P.
    By:   Polaris Venture Management Co. VI, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS VENTURE MANAGEMENT CO. VI, L.L.C.
    By:   *
      Authorized Signatory
    JONATHAN A. FLINT
    By:   *
      Jonathan A. Flint
    TERRANCE G. MCGUIRE
    By:   *
      Terrance G. McGuire
    BRYCE YOUNGREN
    By:   *
      Bryce Youngren
    DAVID BARRETT
    By:   *
      David Barrett
    BRIAN CHEE
    By:   *
      Brian Chee


    CUSIP #80706P103    Page 14 of 14

     

    AMIR NASHAT
    By:   *
      Amir Nashat
    *By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
    Title:   Attorney-in-Fact

    [This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $SRRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    1/9/2026$55.00Buy
    Citigroup
    11/18/2025$42.00Outperform
    Wolfe Research
    10/9/2025$53.00Buy
    BofA Securities
    9/17/2025$45.00Overweight
    Barclays
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    7/17/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Scholar Rock with a new price target

    Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00

    1/9/26 9:07:37 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Scholar Rock with a new price target

    Wolfe Research initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $42.00

    11/18/25 8:27:21 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Scholar Rock with a new price target

    BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00

    10/9/25 8:29:07 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:

    2/18/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Scholar Rock (NASDAQ:SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's

    2/10/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President of R&D Vaishnaw Akshay was granted 47,021 shares, increasing direct ownership by 8% to 642,788 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/11/26 6:13:09 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Sinha Vikas was granted 47,021 shares, increasing direct ownership by 8% to 630,266 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/11/26 6:12:17 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Qatanani Mo was granted 29,258 shares, increasing direct ownership by 34% to 114,918 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    2/11/26 6:11:20 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $1,181,634 worth of shares (29,599 units at $39.92) and exercised 1,064,804 in-the-money shares at a strike of $7.35 (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/16/25 9:07:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $18,807,352 worth of shares (500,439 units at $37.58) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/7/25 8:59:19 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Scholar Rock Holding Corporation

    SCHEDULE 13G - Scholar Rock Holding Corp (0001727196) (Subject)

    2/10/26 11:19:49 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    1/12/26 9:23:39 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Other Events

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    12/2/25 7:00:38 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:

    2/18/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us

    2/13/26 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Scholar Rock (NASDAQ:SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's

    2/10/26 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care